239 results about "Liver function" patented technology

The invention provides a multi-channel one-core multi-detection integrated detection method, which is applied to the technical field of in-vitro diagnosis and comprises the following steps: acquiring time sequence original signals of blood routine, liver function and kidney function channels; obtaining a baseline stable primary signal through cross-channel baseline trend coupling and adaptive correction; adopting a machine learning model to identify interference components and performing component offset to obtain a decoupling signal; mapping the decoupling signal into a physiological parameter value and carrying out rationality test; when the low credible parameter exists, a rechecking mechanism is triggered; performing weighted fusion on the basis of the rationality test result and the recheck signal to obtain a comprehensive parameter set; and finally generating a comprehensive detection report containing the credibility score. Cooperative processing and fusion analysis of multi-channel detection signals are realized, and the accuracy and reliability of a detection result are remarkably improved through interference identification and a dynamic recheck mechanism.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

A microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix for liver regeneration and a preparation method. The hydrogel is prepared by means of combining fish liver decellularized extracellular matrix (dECM) and gelatin methacryloyl (GelMA), and loading induced pluripotent stem cell-derived hepatocytes (iPSC-heps) for liver regeneration. The microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix exhibits excellent biocompatibility, retains intact endogenous growth factors, maintains the biological activity of cells, ensures the effective encapsulation of the cells, and facilitates the robust functional expression of the iPSC-heps. After in-vivo transplantation, the survival rate and liver function of mice with acute liver failure are significantly improved, and liver regeneration and repair are promoted.

The application discloses an animal bifidobacterium producing bile salt hydrolase and application thereof in neonatal jaundice, and belongs to the technical field of microorganisms. The animal bifidobacterium lactis WXM screened by the application has the effect of relieving neonatal jaundice, can significantly improve weight loss of a jaundice individual in an early life stage, improve abnormal increase of a bilirubin level in serum, improve liver damage, improve the level of an enzyme related to liver function, the expression level of a related inflammatory factor in the liver and the expression level of an enzyme UGT1A1 related to bilirubin metabolism, and has the effect of relieving neonatal jaundice. The strain of the application has high safety and has wide application value in the fields of food, functional food, health products, medicine and the like.

The invention discloses a preparation method of crocodile liver peptide for improving liver injury, and relates to the technical field of bioactive peptide extraction, and the preparation method comprises the following steps: crocodile liver pretreatment: cutting fresh crocodile liver into blocks, mixing with deionized water, homogenizing, and adding a zirconium phosphate molecular sieve to obtain crocodile liver homogenate; enzymatic hydrolysis reaction: adjusting the pH value of the homogenate, and adding a compound enzyme preparation for enzymatic hydrolysis; carrying out enzyme deactivation treatment, namely heating, cooling, centrifuging and taking supernate; performing ultrafiltration separation, namely filtering the supernate through an ultrafiltration membrane, and collecting a small molecule peptide solution; purifying and refining: purifying through sephadex column chromatography, and freeze-drying to obtain a crocodile liver peptide product; a double-particle-size zirconium phosphate molecular sieve is constructed to cooperate with a compound enzyme preparation for enzymolysis, electron transfer is enhanced by combining phosphorylation modification, the defects of metal inhibition enzyme activity, insufficient concealed peptide fragment cutting and oxidative damage are overcome, meanwhile, the application of the crocodile liver peptide in the aspect of improving the liver function is researched, and the crocodile liver peptide has a good application prospect. And a new choice is provided for prevention and treatment of liver diseases and liver health care.

The invention discloses a biological medicine application of luwulinine, and provides and verifies that luwulinine can inhibit disulfiram death of cells for the first time, so that luwulinine can be used for preventing or treating hepatic ischemia reperfusion injury. Experimental data show that the luteiniine can relieve liver function injury after reperfusion with cell apoptosis, tissue inflammation infiltration and tissue fibrosis as manifestations, and a new direction is provided for mechanism research and prevention and treatment of hepatic ischemia reperfusion injury.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to fermented lactobacillus mucus with an anti-aging function and application of the fermented lactobacillus mucus. The strain is preserved in Guangdong Microbial Culture Collection Center on August 27, 2025, and the preservation number is GDMCC No: 66877. Experimental results show that the bacterium has excellent oxidation resistance, can relieve oxidative damage, delay senescence and inhibit senescence-related gene expression, shows the capabilities of improving memory reproduction capability decline caused by senescence, improving body anti-inflammatory capability and improving intestinal flora imbalance induced by senescence, and can regulate fat factor level and improve energy metabolism, so that the function of resisting senescence is achieved. And the polypeptide shows the potential of resisting fat deposition and protecting liver functions. Therefore, the strain can be used for developing products with multiple beneficial functions of delaying senescence, contributing to resisting oxidation, assisting in improving memory, contributing to regulating intestinal flora and the like, has the advantages of high safety, strong gastrointestinal tract tolerance and good colonization ability, and has a very good application value.

The invention discloses a pharmaceutical composition for improving liver dysfunction, the pharmaceutical composition comprises a tablet core and a coating film, the tablet core comprises 30-40 parts of mono-ammonium glycyrrhizinate (20-30 parts by weight of glycyrrhizin), 20-30 parts of glycine, 20-30 parts of methionine, 55-65 parts of a filler, 2-10 parts of a disintegrating agent, 1-10 parts of an adhesive and 1-10 parts of a lubricant, and the coating film is a gastric soluble film coating; wherein the filling agent is formed by compounding lactose, microcrystalline cellulose, calcium carbonate, calcium hydrophosphate and mannitol, the mass ratio of the lactose to the microcrystalline cellulose to the calcium carbonate to the calcium hydrophosphate to the mannitol is (1-24): (1-35): (1-25): (1-9): (1-9), and the pharmaceutical composition for improving liver dysfunction has good dissolution and stability.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The invention discloses a probiotic strain Bifidobacterium animalis subsp. Lactiss S8 of a high-yield biological membrane, the preservation number is GDMCC NO.66518, the characteristics of the stable high-yield biological membrane are obtained through directional screening and adaptive evolution, and the yield of the biological membrane is three times higher than that of a positive control. The extracellular polymeric substance (EPS) of the strain can significantly enhance the tolerance of the strain to severe environments such as gastric acid, cholate and the like, and improve the intestinal colonization ability. Experiments prove that the strain remarkably reduces two liver function indexes, namely ALT and AST, in an animal model, and shows that the strain has a certain effect of improving liver injury.

The invention relates to a lycium barbarum fermented product with a liver protection function as well as a preparation method and application thereof, and belongs to the technical field of fermentation. The fermentation liquor is prepared by taking a specific traditional Chinese medicine compound consisting of radix puerariae, semen hoveniae, fructus lycii, rhizoma polygonati, flos chrysanthemi, pericarpium citri reticulatae and cordyceps militaris as a matrix through a double-bacterium synergistic fermentation process. The preparation method comprises the following steps: firstly, pre-fermenting a compound extract by using Akkermansia muciniphila bacteria, enriching propionic acid and optimizing the matrix; the preparation method comprises the following steps: carrying out primary fermentation by using lactic acid bacteria combined with Lactobacillus paracasei E10, L. paracasei JN-1 and L. paracasei JN-8 (in a volume ratio of 3: 3: 2), and carrying out secondary fermentation by using lactobacillus combined with Lactobacillus paracasei E10, L. paracasei JN-1 and L. paracasei JN-8 (in a volume ratio of 3: 3: 2). The traditional Chinese medicine composition realizes double synergy of efficient conversion of traditional Chinese medicine active ingredients and intestinal-hepatic axis regulation and control, and is suitable for prevention and adjuvant therapy of alcoholic liver injury and non-alcoholic fatty liver disease.

The invention belongs to the technical field of medical information processing, and particularly discloses a regression model establishment method and system for detecting related indexes of myocardial cells of Wuzhishan pigs by using blood biochemical indexes, and the method comprises the following steps: collecting blood and heart tissue samples of the Wuzhishan pigs at different month ages, detecting the blood biochemical indexes including liver function, blood fat and blood sugar indexes, and establishing a regression model for detecting the related indexes of myocardial cells of the Wuzhishan pigs. Related indexes of myocardial cells; analyzing the index expression quantity difference, and screening significant difference indexes; then calculating the correlation between the remarkably different blood biochemical indexes and myocardial cell related indexes, and determining high-correlation blood biochemical indexes; and finally, constructing a first version of multiple regression model by respectively taking the myocardial enzyme index and the myocardial cell related index as dependent variables and the high-correlation blood biochemical index as an independent variable, removing outliers and updating the sample set on the basis of the first version of multiple regression model, and constructing a second version of multiple regression model by utilizing the new sample set, and on the basis of the second version of multiple regression model, constructing a third version of multiple regression model by adopting a stepwise regression method. According to the method, related indexes of myocardial cells can be accurately deduced through blood biochemical indexes, and support is provided for Wuzhishan pig heart disease research and model animal research and development.

The invention provides a pharmaceutical composition for treating liver injury and hepatic fibrosis, and relates to the technical field of biological medicines. The pharmaceutical composition is prepared from a peucedanum decursum extract, a penthorum chinense pursh extract, a spanishneedles herb extract and a nux prinsepiae extract. The pharmaceutical composition shows an excellent protective effect on a carbon tetrachloride induced hepatocyte injury model. The pharmaceutical composition disclosed by the invention has obvious treatment and protection effects on carbon tetrachloride induced rat hepatic fibrosis, and the anti-hepatic fibrosis effect is realized by improving four indexes of liver function and hepatic fibrosis, reducing the level of inflammatory factors in the liver and relieving inflammatory reaction in the hepatic fibrosis process. The pharmaceutical composition disclosed by the invention is expected to be further developed and popularized as a medicine for treating liver injury and hepatic fibrosis.

To provide an endoplasmic reticulum stress suppressing composition and a liver function improving composition.SOLUTION: A composition for suppressing endoplasmic reticulum stress and / or a composition for improving hepatic functions, comprising one or more plants selected from the group consisting of Plantago asiatica, Hamilton's spindle tree, panicled hydrangea, Japanese plum yew, Japanese mallotus, and Papaver rhoeas, and / or an extract thereof.SELECTED DRAWING: None

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

Methods are provided for effectively distinguishing the abilities of a human liver and an extracorporeal liver in an extracorporeal liver perfusion system to extract cholate and, thus, measure relative liver function.

The application discloses application of pyrroloquinoline quinone (PQQ) or a derivative thereof in preparation of a product for relieving or preventing blue-green algae toxin poisoning of yellow catfish, and belongs to the technical field of aquatic animal feed. The PQQ or the derivative thereof can be used as an aquatic feed additive or a medicine, and is added in an amount of 3-6 mg / kg of feed to feed yellow catfish, so as to effectively relieve pathological damage of the liver of the yellow catfish caused by blue-green algae toxin through various ways such as improving key enzyme activity of liver function, inhibiting liver oxidative stress, relieving inflammatory reaction and reducing structural damage of tissues. The PQQ is a new food raw material approved in China in 2022, has advantages of high safety, good water solubility, moderate cost, similar dosage to that of feed vitamins and the like, and provides a safe, economical and convenient new nutritional intervention strategy for blue-green algae toxin poisoning of the yellow catfish, and has a wide industrial application prospect.

The invention relates to the field of biological medicines, and discloses an application of an anti-thymocyte immune globulin preparation in liver transplantation immune induction, which comprises a use method and a dosage of anti-thymocyte immune globulin as an immune inducer in a liver transplantation recipient. Clinical cases prove that liver transplantation recipients use the anti-thymocyte immune globulin as immunosuppressive induction, so that the liver function and lymphocyte level can be quickly recovered to normal ranges, no obvious influence is caused on renal function, the occurrence rate of acute rejection reaction is reduced, the cytomegalovirus infection rate is not increased, and the anti-thymocyte immune globulin can be applied to liver transplantation recipients. Clinical application of the anti-thymocyte immune globulin in immune induction treatment of liver transplantation recipients is expanded, and the anti-thymocyte immune globulin has a great application prospect.

According to the application of the E3 ligase UFL1 modified by the Especially in clearing the SHBs / HBsAg, the SHBs / HBsAg can be cleared by inhibiting the expression of the E3 ligase UFL1 modified by the Especially, so that the effect of treating HBV infection or HBV related diseases is achieved. The strategy of the invention is to directly target and remove the existing SHBs / HBsAg protein, and the action is more direct and rapid. According to the present invention, the inherent protein mass control system (proteasome pathway) of cells is utilized, such that the high biocompatibility and the low off-target toxicity can be provided; and the combination of the strategy and the existing antiviral drugs is expected to further significantly improve the functional cure rate of hepatitis B.

The invention provides a composition and a medicine for preventing and treating acute liver injury and protecting liver. The composition comprises sweet orange flavone and dauricine. According to the traditional Chinese medicine composition disclosed by the invention, through a large number of researches, the sweet orange flavone and the dauricine can be synergistically interacted when being used for preventing and treating the acute liver injury; the sweet orange flavone and dauricine combined treatment group can more effectively relieve liver dysfunction, tissue injury and inflammatory state of acute liver injury model mice. Therefore, the combination of the sweet orange flavone and the dauricine can more effectively prevent and treat the acute liver injury and related diseases of the acute liver injury, and has the effect of protecting the liver.

This invention discloses a method for preparing a co-loaded dual-gene targeted delivery system and its application, involving the construction and preparation of a dual-gene (pHNF4α, pFOXA3) delivery system. This delivery system can target myofibroblasts (MFs) and activated hepatic stellate cells (aHSCs) and can be used for gene therapy of liver fibrosis. This invention synthesizes the targeting carrier material PEI. 25K -PEG 2K -pPB, through electrostatic adsorption, combines with pHNF4α and pFOXA3 to form a co-loaded dual-gene targeted delivery system, F4α / A3@PP-pPB. This delivery system, through the targeting group pPB, binds to MFs (metacellular matrix cells) that lead to excessive accumulation of extracellular matrix in fibrotic livers and to PDGFR (polydimethylformamide) highly expressed on the surface of aHSCs. On the one hand, it inhibits the activation of aHSCs; on the other hand, it transdifferentiates MFs into hepatocyte-like cells (iHep). These two modes, while combating liver fibrosis, can also achieve a certain degree of liver function reconstruction through transdifferentiated iHep cells, providing new ideas and methods for the effective treatment of liver fibrosis.

The invention discloses a fructus gardeniae and szechwan chinaberry fruit composition and application thereof in liver protection, and belongs to the technical field of biological medicines. The invention provides a cape jasmine fruit and szechwan chinaberry fruit composition, and the proportion of cape jasmine fruit to szechwan chinaberry fruit is (1-2): (1-6), optimally 2: 3. The cape jasmine and szechwan chinaberry fruit composition can be used as an activating agent of DBP; experiments prove that after overexpression of the DBP, the expression quantities of metabolic genes Cyp2a4, ALB, G6PC and Sult1c1 are remarkably increased, which indicates that overexpression of the DBP can promote liver functions. The fructus gardeniae and szechwan chinaberry fruit composition or overexpression DBP provided by the invention can play the role of resisting oxidation and protecting the liver by adjusting an antioxidant function gene, a new thought and strategy are provided for treatment of liver diseases, and an important scientific basis is provided for development of a natural small-molecule DBP agonist.

The invention belongs to the technical field of medicine research, and particularly relates to a gentiana macrophylla extract as well as a preparation method and application thereof. The preparation method of the gentiana macrophylla extract comprises the following steps: by taking gentiana macrophylla as a raw material, adding an ethanol solution with the mass fraction of 70-80%, carrying out heating reflux extraction, collecting an extracting solution, and concentrating to obtain a crude gentiana macrophylla extract; taking an aqueous solution of the gentiana macrophylla crude extract, extracting by taking petroleum ether as an extracting agent, reserving water layer liquid, and drying to obtain a water layer sample; the water layer sample is eluted through macroporous adsorption resin, pure water and an ethanol solution with the mass fraction being 35%-40% are sequentially used as eluents, ethanol eluent is collected and dried, and the water layer sample is obtained. Tests prove that the gentiana macrophylla extract can improve the MASH damp-heat accumulation symptom and liver functions, inhibit the increase of liver proinflammatory cytokines, and relieve MASH hepatic lobule cell fat accumulation, foam and balloon-like degeneration, cell nucleus atrophy and inflammatory lesions.

The application belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to a fermented Lactobacillus muci genus with a function of delaying aging and application thereof. The bacterium was preserved in the Guangdong Microbial Culture Collection Center on August 27, 2025, and the preservation number is GDMCC No: 66877. Experimental results show that the bacterium has excellent antioxidant performance, can relieve oxidative damage, delay aging, inhibit the expression of aging-related genes, and has the ability to improve the memory reproduction ability decline caused by aging, improve the body's anti-inflammatory ability, improve the intestinal flora imbalance induced by aging, and can regulate the level of fat factors, improve energy metabolism, and has the potential of anti-fat deposition and protection of liver function. Therefore, the bacterium can be used to develop products with multiple beneficial functions such as delaying aging, helping to antioxidant, auxiliary improving memory, helping to regulate intestinal flora, and has the advantages of high safety, strong gastrointestinal tolerance, good colonization ability, and has good application value.

The present invention relates to a protective agent selected from the group consisting of L-glutamine, L-alanyl-L-glutamine, L-glutamyl-L-alanine, L-glutamyl-L-glycine, L-glycyl-L-glutamine, or a mixture thereof, and to a method for preparing the protective agent, the present invention relates to a protective agent for use in the prevention and / or treatment of diseases associated with end-stage nephropathy (ESKD) mediated by liver dysfunction induced by peritoneal dialysis treatment, specifically for the prevention and / or treatment during peritoneal dialysis treatment: (A) liver diseases induced by said peritoneal dialysis treatment and / or (B) diseases associated with ESKD mediated by liver dysfunction induced by said peritoneal dialysis treatment, wherein said protective agent is administered by intraperitoneal administration.

The invention discloses application of Psammatlysene D and a derivative thereof in preparation of a medicine for resisting chronic liver diseases, and belongs to the technical field of medicines. The technical scheme of the invention comprises the application of the Psammaglyene D in preparation of a product for resisting chronic liver diseases. The Psammatlyene D can inhibit the growth of LX2 cells, reduce liver function indexes ALT and AST, and relieve the degree of hepatic fibrosis in a mouse body; the growth of liver cancer cells can be inhibited in vivo and in vitro, and a synergistic effect can be generated with sorafenib; meanwhile, the anti-proliferation ability is also shown in sorafenib drug-resistant liver cancer. The derivative B12 of the Psammatlysene D has a stronger in-vitro anti-hepatic fibrosis effect, and the C11 has a very weak inhibition capability on hERG (human endothelial growth factor) and has no potential cardiotoxicity. The results show that the Psammaglyene D has relatively strong capabilities of resisting hepatic fibrosis, inhibiting liver cancer development and relieving sorafenib drug-resistant liver cancer, and the Psammaglyene D and C11 can be used as potential lead compounds for the development of anti-hepatic fibrosis and anti-liver cancer drugs, and are finally applied to the treatment of chronic liver diseases.

The invention belongs to the technical field of biological medicines, and particularly discloses application of a CD44 function inhibitor in preparation of a medicine for preventing or relieving radiation liver injury (RILD). Radioactive liver injury is often caused by hepatocellular carcinoma radiotherapy, and specific targeting drugs are lacked clinically. It is revealed for the first time that whether CD44 molecules on the surface of Kuhu cells are highly expressed after radiation, and the CD44 molecules are key hubs for driving RILD; the invention also provides a CD44 function inhibitor which is a specific targeting drug aiming at RILD, and the action mechanism of the CD44 function inhibitor is to effectively block polarization of radiation-induced Kuptake cells to pro-inflammatory phenotype by inhibiting the CD44 function, so that local inflammatory response, oxidative stress and hepatocyte injury of the liver are relieved. Experiments prove that the CD44 function inhibitor can relieve liver inflammation, improve liver function indexes and reduce liver cell death and tissue pathological damage, and a brand-new and targeted scheme for preventing and treating RILD is provided.

Methods of treating non-metastatic castration-resistant prostate cancer in a subject having severe liver damage are provided.SOLUTION: Provided are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor comprising 4 - [7 - (6-cyano-5-trifluoromethylpyridin-3-yl) - 8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl] - 2-fluoro-N-methylbenzamide (apalutamide).SELECTED DRAWING: None

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

The invention provides an mRNA nucleic acid medicine and application thereof. The mRNA comprises a nucleic acid with a nucleotide sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 3. The mRNA can be used for treating hepatic fibrosis, relieving clinical hepatic fibrosis, inhibiting the progress of hepatic fibrosis, promoting liver cancer cells to differentiate into hepatic cells with partial liver functions, recovering the liver functions and prolonging the survival time of HCC patients.